Cushman & Wakefield (CWK) Earnings Analysis
Cushman & Wakefield (CWK) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS 0.15 USD vs 0.13 USD est (+15.4%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 38.81.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CWK next report earnings?
No confirmed upcoming earnings date is currently scheduled for CWK. This page updates as the calendar is published.
CWK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.15 USD | 0.13 USD | +15.4% | Beat |
| 2026-02-19 | -0.0982 USD | 0.53 USD | -118.5% | Miss |
| 2025-10-30 | 0.29 USD | 0.28 USD | +3.6% | Beat |
| 2025-02-20 | 0.48 USD | 0.45 USD | +6.7% | Beat |
| 2024-11-04 | 0.23 USD | 0.2 USD | +15% | Beat |
| 2024-07-29 | 0.2 USD | 0.18 USD | +11.1% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
CWK valuation and analyst view
| Trailing P/E | 38.81 |
|---|---|
| Trailing EPS | 0.31658 USD |
| Price / book | 1.49 |
| Dividend yield | 0.00% |
| Market cap | 2.91B |
| Analyst consensus | Hold (7 buy / 8 hold / 1 sell) |
| Avg price target | 17 USD |
Related research pages
Frequently asked questions
When is Cushman & Wakefield (CWK)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CWK. This page updates as the calendar is published.
Did CWK beat earnings last quarter?
In its 2026-05-07 report, CWK posted EPS of 0.15 USD versus a 0.13 USD estimate — a beat of 15.4%.
What is CWK's earnings track record?
Over the last 6 reported quarters with consensus data, CWK beat estimates 5 times (83%).
What is CWK's current P/E ratio and EPS?
CWK trades at a trailing P/E of 38.81 on trailing EPS of 0.3165807560137457 USD.
What do analysts rate CWK?
Analyst consensus is "Hold" across 16 ratings (0 strong buy, 7 buy, 8 hold, 1 sell, 0 strong sell). Average 12-month price target: 17 USD.